Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)

University Hospital, Geneva2,498 enrolled

Overview

To demonstrate the effectiveness of the ELIPS programme (Multi-dimEnsionaL preventIon Program after Acute coronary Syndrome), which aims at improving quality of care of patients admitted to hospital with Acute Coronary Syndrome (ACS) in the Swiss setting. The program targets an increase in prescription rates by physicians and long term medication adherence and adoption of healthy lifestyle attitudes by patients. The program is dedicated to caregivers to increase their application of guidelines into practice, to increase their confidence in therapeutic education of patients, and to patients to improve their understanding of ACS and its treatment and to increase their motivation for long term treatment,.

Study Type

OBSERVATIONAL

Enrollment

2,498

Conditions

Acute Coronary Syndrome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients \>18 years * Admitted for an ACS, that is with symptoms compatible with angina pectoris (chest pain, breathlessness) and at least one of the following 3 features : a) Elevation or depression of the ST segment, inverted T waves or dynamic changes in the repolarization phase b) Positive troponin c) Known coronary artery disease. A significant coronary artery disease must be confirmed angiographically. Exclusion Criteria: * Severe physical disability or dement * Less than 1 year of life expectancy for non cardiac reason

Locations (4)

University Hospital

Bern, Switzerland

University Hospitals

Geneva, Switzerland

University Hospital

Lausanne, Switzerland

University Hospital,

Zurich, Switzerland

Outcomes

Primary Outcomes

composite of death and cardiovascular event

Composite of * death from any cause, * myocardial infarction, * documented unstable angina requiring rehospitalization, * revascularization (performed at least 30 days after randomization), * documented new or worsen lower limb ischemia, * stroke * transient cerebral ischemic accident.

Time frame: 1 year

Secondary Outcomes

Process outcome at discharge

Prescription of recommended treatment at discharge: * Cardiovascular medication (Lipid lowering treatment, beta-blockers, antithrombotic therapy (acetylsalicylic acid, clopidogrel), ACE-inhibitors, AT-II antagonists) * Smoking cessation counseling during hospital stay * Referral to cardiovascular rehabilitation center * Use of educational booklet at discharge

Time frame: 1 year

Clinical outcomes at follow-up

Individual data on each of the composite outcome Cardiovascular mortality

Time frame: 1 year

Surrogate outcomes at follow-up

Cardiovascular risk factor control at follow-up: * arterial blood pressure, * fasting blood glucose, * blood lipids (LDL-Cholesterol, HDL-Cholesterol, Triglycerides), * smoking cessation (7-days point prevalence at one year and continuous abstinence since hospitalisation) * body mass index reduction * abdominal waist reduction Quality of life and utility (EQ-5D questionnaire) Adherence to medication (MAS questionnaire) Physical activity (IPAQ questionnaire) Motivation to adopt therapeutic lifestyle attitudes (smoking cessation, diet change, physical activity)

Time frame: 1 year